Bioenergetics and synaptic plasticity as potential targets for individualizing treatment for depression

Grants

Funding Acknowledgements

JBP is supported by a Deakin University Postgraduate Award. MB is supported by a NHMRC Senior Principal Research Fellowship (GNT1059660) and has received Grant/Research Support from the NIH, Cooperative Research Centre, Simons Autism Foundation, Cancer Council of Victoria, Stanley Medical Research Foundation, MBF, NHMRC, Beyond Blue, Rotary Health, Geelong Medical Research Foundation, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Meat and Livestock Board, Organon, Novartis, Mayne Pharma, Servier, Woolworths, Avant and the Harry Windsor Foundation, and has been a speaker for Astra Zeneca, Bristol Myers Squibb, Eli Lilly, Glaxo SmithKline, Janssen Cilag, Lundbeck, Merck, Pfizer, Sanofi Synthelabo, Servier, Solvay and Wyeth, and served as a consultant to Allergan, Astra Zeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Eli Lilly, Grunbiotics, Glaxo SmithKline, Janssen Cilag, Livallova, Lundbeck, Merck, Mylan, Otsuka, Pfizer, and Servier. KW and SLM have received grant support from NHMRC. MAF has received grant support from AssureRx, Myriad, NIAAA, NIMH, and Pfizer, and has served as a consultant for Janssen, Mitsubishi Tanabe Pharma Corporation, Myriad, Neuralstem Inc., Otsuka American Pharmaceutical, Sunovion, and Teva Pharmaceuticals. SJT has received Grant/Research Support from the State of Minnesota, TEVA pharmaceuticals, International Bipolar Foundation, Brain & Research Foundation, and Mayo Clinic Center for Individualized Medicine. SE has received grant support from AstraZeneca and Jansen Pharmaceuticals as principal investigator, has served as a one-off speaker for Roche pharmaceuticals, Eli Lilly, Bristol Myers Squibb and participated in workshops organized by Otsuka Pharmaceuticals. The other authors report no biomedical financial interests of potential conflicts of interest.